Skip to main
HUM

Humana (HUM) Stock Forecast & Price Target

Humana (HUM) Analyst Ratings

Based on 18 analyst ratings
Hold
Strong Buy 11%
Buy 22%
Hold 61%
Sell 6%
Strong Sell 0%

Bulls say

Humana has demonstrated a positive trajectory in its earnings potential, with an increased 2025 EPS estimate raised to $17.06, reflecting strong second-quarter results and revised guidance. Furthermore, the company anticipates year-over-year earnings growth in 2027 driven by effective margin initiatives, solidifying its operational efficiency despite potential challenges in bonus payments. Humana's above-industry star rating profile in the Medicare Advantage segment positions the firm competitively, enabling resilience against regulatory and reimbursement fluctuations.

Bears say

Humana's financial outlook appears negative due to anticipated declines in earnings per share (EPS) for 2026, attributed to ongoing challenges such as increased Medicare Advantage (MA) utilization and heightened competition, which complicate margin recovery initiatives. The company is also facing potential headwinds from inadequate reimbursement rates and declining Star ratings, which could further impact its financial performance and growth in Healthcare Services. Adjustments to EPS estimates reflect concerns over sustaining profitability amid these operational challenges, with projections for FY27 indicating a possible shortfall of approximately 10% due to necessary investments for recovery efforts.

Humana (HUM) has been analyzed by 18 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 22% recommend Buy, 61% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humana (HUM) Forecast

Analysts have given Humana (HUM) a Hold based on their latest research and market trends.

According to 18 analysts, Humana (HUM) has a Hold consensus rating as of Feb 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $287.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $287.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humana (HUM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.